Compounds > etidronate
Page last updated: 2024-10-26

etidronate and Pain

etidronate has been researched along with Pain in 98 studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis."9.11[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005)
"Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain."9.09[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. ( Csernay, L; Láng, J; Pajor, L; Pávics, L; Róka, R; Séra, T; Thurzó, L, 2000)
"QBS-measured radiation doses of (186)Re etidronate in painful metastases are a good predictor of pain relief."9.09Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. ( Betman, L; Frenkel, A; Front, D; Iosilevski, G; Israel, O; Keidar, Z; Kolodny, GM; Kuten, A; Rubinov, R; Yarnitsky, D, 2000)
"Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts)."9.09[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. ( Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R, 2000)
"Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases."9.08[Pain therapy with rhenium-186 HEDP in multiple bone metastases]. ( Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P, 1996)
" We have evaluated etidronate disodium, a diphosphonate commonly prescribed in the United Kingdom for Paget's disease in patients with rheumatoid arthritis."9.06A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. ( Bird, HA; Dixon, JS; Hill, J; Sitton, NG; Wright, V, 1988)
"To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (89Sr) in patients with painful osteoblastic metastases primarily from prostate and breast cancer."8.79Strontium 89 therapy for the palliation of pain due to osseous metastases. ( Baxter, KG; Preston, DF; Robinson, RG; Schiefelbein, M, 1995)
"The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with (186)Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer."7.75Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. ( Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009)
"The aims of the present study were to determine whether patients with painful bone metastases from primary cancer sites showed a higher level of a bone resorption marker than those with no evidence of skeletal-related events, and to clarify the efficacy of oral administration of etidronate for pain due to bone metastases and bone resorption."7.71Transient relief of metastatic cancer bone pain by oral administration of etidronate. ( Ichimura, S; Iwamoto, J; Takeda, T, 2002)
"For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate (HEDP) is efficient in pain palliation of disseminated bone metastases."7.70Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. ( Bender, H; Biersack, HJ; Carl, UM; Dierke-Dzierzon, C; Krebs, D; Palmedo, H; Risse, J, 1999)
"Etidronate and perhaps bisphosphonates, in general, should be considered in the management of refractory metastatic bone pain, particularly in the hospice population."7.69Use of a bisphosphonate (etidronate) to improve metastatic bone pain in three hospice patients. ( Gloth, FM, 1995)
" Oral etidronate given daily showed no clinical benefit, whereas the use of oral clodronate daily did reduce the development of new osteolytic lesions but did not significantly affect bone pain or rates of pathologic fractures."6.18Bisphosphonates in multiple myeloma. ( Berenson, JR, 1997)
"A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38."5.31Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy. ( Franke, WG; Hliscs, R; Kropp, J; Liepe, K, 2000)
"To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis."5.11[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005)
"Rhenium-188-HEDP ((188)Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain."5.10Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. ( Kotzerke, J; Kropp, J; Liepe, K; Runge, R, 2003)
"Although etidronate is effective, risedronate offers a shorter duration of therapy, better and longer-lasting remission, significant reductions in pain, and provides additional remission in subjects who exhibited an incomplete response to previous etidronate treatment."5.09A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. ( Axelrod, DW; Bekker, PJ; Brown, JP; Hoseyni, MS; Miller, PD; Siris, ES, 1999)
"Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts)."5.09[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. ( Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R, 2000)
"Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a new radiopharmaceutical for treatment of metastatic bone pain."5.09[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]. ( Csernay, L; Láng, J; Pajor, L; Pávics, L; Róka, R; Séra, T; Thurzó, L, 2000)
"QBS-measured radiation doses of (186)Re etidronate in painful metastases are a good predictor of pain relief."5.09Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. ( Betman, L; Frenkel, A; Front, D; Iosilevski, G; Israel, O; Keidar, Z; Kolodny, GM; Kuten, A; Rubinov, R; Yarnitsky, D, 2000)
" Other end points included changes in urinary deoxypyridinoline excretion, pain, functional impairment scores, and radiological osteolysis."5.08Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. ( Altman, R; Conte, JM; Favus, M; Lombardi, A; Lyles, K; McIlwain, H; Murphy, WA; Reda, C; Rude, R; Seton, M; Siris, E; Thompson, D; Tiegs, R; Tucci, JR; Weinstein, RS; Yates, AJ; Zimering, M, 1996)
"Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases."5.08[Pain therapy with rhenium-186 HEDP in multiple bone metastases]. ( Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P, 1996)
" We have evaluated etidronate disodium, a diphosphonate commonly prescribed in the United Kingdom for Paget's disease in patients with rheumatoid arthritis."5.06A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. ( Bird, HA; Dixon, JS; Hill, J; Sitton, NG; Wright, V, 1988)
"To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (89Sr) in patients with painful osteoblastic metastases primarily from prostate and breast cancer."4.79Strontium 89 therapy for the palliation of pain due to osseous metastases. ( Baxter, KG; Preston, DF; Robinson, RG; Schiefelbein, M, 1995)
"The aim of this study was to compare pain response and hematologic toxicity between single and multiple therapies with (186)Re-HEDP under zoledronic acid in patients suffering from painful osseous metastases from prostate or breast cancer."3.75Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. ( Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A, 2009)
"The aims of the present study were to determine whether patients with painful bone metastases from primary cancer sites showed a higher level of a bone resorption marker than those with no evidence of skeletal-related events, and to clarify the efficacy of oral administration of etidronate for pain due to bone metastases and bone resorption."3.71Transient relief of metastatic cancer bone pain by oral administration of etidronate. ( Ichimura, S; Iwamoto, J; Takeda, T, 2002)
"For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate (HEDP) is efficient in pain palliation of disseminated bone metastases."3.70Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. ( Bender, H; Biersack, HJ; Carl, UM; Dierke-Dzierzon, C; Krebs, D; Palmedo, H; Risse, J, 1999)
" When used orally, it can, as can pamidronate, reduce the skeletal complications of breast cancer such as hypercalcemia, bone fractures and bone pain."3.69Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995)
"Etidronate and perhaps bisphosphonates, in general, should be considered in the management of refractory metastatic bone pain, particularly in the hospice population."3.69Use of a bisphosphonate (etidronate) to improve metastatic bone pain in three hospice patients. ( Gloth, FM, 1995)
"Localised foot pain occurred in four patients with Paget's disease of bone or myositis ossificans who were treated with disodium etidronate (EHDP) in a dose of 10 to 20 mg/kg body weight/day for four to six months."3.66Diphosphonates and painful feet. ( Evans, RA; MacDonald, D, 1983)
"Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis."2.76Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36. ( Fujii, Y; Fujita, T; Miyauchi, A; Nakajima, M; Ohue, M; Takagi, Y, 2011)
"In total, 79 patients (18 with breast cancer and 61 with prostate cancer) were treated (31 patients with 188Re-HEDP, 15 patients each with 186Re-HEDP and 153Sm-EDTMP, and 18 patients with 89Sr)."2.73A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. ( Kotzerke, J; Liepe, K, 2007)
" The dosage of opiates was decreased in 77% of the patients and could be discontinued in 4 of them."2.71Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer. ( Anagnostopoulou, US; Datseris, EI; Leondi, AH; Leontopoulou, SA; Papadaki, EK; Rapti, AS; Souvatzoglou, MA; Zerva, CJ, 2004)
" We have evaluated the effectiveness of three dosage regimes of aminohydroxypropylidene bisphosphonate (pamidronate) in 15 patients with extensive Paget's disease who had become refractory to conventional therapy."2.67Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. ( Gunasekera, RD; Wimalawansa, SJ, 1993)
"Prevention of stress fractures has been studied in military personnel, but more research is needed in other populations."2.47Stress fractures: diagnosis, treatment, and prevention. ( Kapil, N; Patel, DS; Roth, M, 2011)
"Many patients with cancer develop symptomatic skeletal metastases at an advanced stage of their disease."2.44Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. ( de Klerk, JM; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2007)
"Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures."2.41Bisphosphonates in multiple myeloma. ( Kanis, JA; McCloskey, EV, 2000)
"Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity."2.40Bisphosphonates and breast carcinoma. ( Lipton, A, 1997)
"It is an effective inhibitor of bone resorption, but unlike etidronate does not impair the mineralization of bone."2.40Clodronate. ( Kanis, JA; McCloskey, EV, 1997)
" Their use as single agents with dose escalations, in combination with biphosphonates or chemotherapy is well known in the peer-reviewed literature; however, little is known about the combination between different agents."1.39Radionuclide therapy of painful bone metastases--a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness. ( Gouliamos, A; Limouris, GS; Sideras, PA; Stavraka, A, 2013)
"Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment."1.38The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. ( Hayakawa, Y; Iinuma, N; Itoh, M; Iwayama, S; Kamisaki, T; Nakamura, T; Nishikawa, M; Osawa, M; Suzuki, H; Yamaguchi, H, 2012)
"This case demonstrates that heterotopic ossification may occur and be a source of residual limb pain in the adult nontraumatic amputee population."1.36Heterotopic ossification in the residual lower limb in an adult nontraumatic amputee patient. ( Atkinson, GJ; Lee, MY; Mehta, MK, 2010)
"Risedronate decreased bone cancer-related bone destruction and pain-related behavior and decreased the spinal expression of glial fibrillary acidic protein, whereas NE-10790 had no effect on these parameters."1.35Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. ( Croucher, PI; Ding, M; Ebetino, FH; Gallagher, O; Hald, A; Hansen, RR; Heegaard, AM; Kassem, M; Thomsen, MW, 2009)
"Pamidronate treatment (60 mg/day for 3 days) was repeated in patients without evidence of PDB remission at day 120."1.32Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. ( Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R, 2004)
"Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment."1.31[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002)
"A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38."1.31Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy. ( Franke, WG; Hliscs, R; Kropp, J; Liepe, K, 2000)
"Paget's disease of bone is a process of increased bone remodeling resulting in architecturally abnormal bone that may affect any area of the skeleton."1.27Current concepts of Paget's disease of bone. ( Lane, JM; Merkow, RL, 1984)
"Paget's disease of bone in 51 patients was treated with ethane-1, hydroxy-1,1 diphosphonate (EHDP) for six months at a dosage of 5 mg/kg/day."1.27Treatment of Paget's disease of bone with ethane-1, hydroxy-1,1 diphosphonate (EHDP) at a low dosage (5 mg/kg/day). ( Alexandre, CM; Chapuy, MC; Edouard, C; Johnston, CC; Meunier, PJ; Vignon, E, 1983)

Research

Studies (98)

TimeframeStudies, this research(%)All Research%
pre-199018 (18.37)18.7374
1990's26 (26.53)18.2507
2000's38 (38.78)29.6817
2010's16 (16.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sharma, R1
Kumar, C1
Mallia, MB2
Kameswaran, M2
Sarma, HD2
Banerjee, S3
Dash, A1
Pirayesh, E1
Amoui, M1
Mirzaee, HR1
Tabei, F1
Rakhsha, A1
Kalantari, BA1
Shafiei, B1
Assadi, M1
Asli, IN1
ter Heine, R1
Lange, R1
Breukels, OB1
Bloemendal, HJ1
Rummenie, RG1
Wakker, AM1
de Graaf, H1
Beekman, FJ1
van der Westerlaken, MM1
Malingré, MM1
Wielders, JP1
van den Berg, L1
Hendrikse, NH1
de Klerk, JM3
Shima, K1
Nemoto, W1
Tsuchiya, M1
Tan-No, K1
Takano-Yamamoto, T2
Sugawara, S2
Endo, Y2
Shinto, AS1
Kamaleshwaran, KK1
Kalarikal, R1
Aswathy, KK1
Hald, A1
Hansen, RR1
Thomsen, MW1
Ding, M1
Croucher, PI1
Gallagher, O1
Ebetino, FH1
Kassem, M1
Heegaard, AM1
Zafeirakis, A2
Zissimopoulos, A2
Baziotis, N2
Limouris, GS3
Atkinson, GJ1
Lee, MY1
Mehta, MK1
Fujita, T2
Ohue, M1
Nakajima, M1
Fujii, Y2
Miyauchi, A2
Takagi, Y2
Cheng, A1
Chen, S1
Zhang, Y1
Yin, D1
Dong, M1
Chiacchio, S1
Mazzarri, S1
Lorenzoni, A1
Nyakale, N1
Boni, G1
Borsò, E1
Alsharif, A1
Grosso, M1
Manca, G1
Greco, C1
Volterrani, D1
Mariani, G1
Patel, DS1
Roth, M1
Kapil, N1
Ozkal-Baydin, P1
Gümüş-Akay, G1
Varol, N1
Rüstemoğlu, A1
Köroğlu, R1
Yüksel, S1
Küçük, O1
Aras, G2
Ibiş, E2
Sunguroğlu, A1
Meulenbeld, HJ1
van Werkhoven, ED1
Coenen, JL1
Creemers, GJ1
Loosveld, OJ1
de Jong, PC1
Ten Tije, AJ1
Fosså, SD1
Polee, M1
Gerritsen, W1
Dalesio, O1
de Wit, R1
Nakamura, T1
Osawa, M1
Itoh, M1
Yamaguchi, H1
Iinuma, N1
Hayakawa, Y1
Suzuki, H1
Kamisaki, T1
Iwayama, S1
Nishikawa, M1
Kim, S1
Seiryu, M1
Okada, S1
Kuroishi, T1
Sideras, PA1
Stavraka, A1
Gouliamos, A1
Iwamoto, J1
Takeda, T1
Ichimura, S1
Minne, HW1
Pollähne, W1
Pfeifer, M1
Begerow, B1
Hinz, C1
Liepe, K5
Kropp, J3
Runge, R3
Kotzerke, J3
Scheffler, J1
Derejko, M1
Bandurski, T1
Romanowicz, G1
Zhang, H2
Tian, M2
Li, S2
Liu, J2
Tanada, S1
Endo, K1
Lam, MG2
van Rijk, PP2
Rendina, D1
Mossetti, G1
Viceconti, R1
Sorrentino, M1
Nunziata, V1
Leondi, AH1
Souvatzoglou, MA1
Rapti, AS1
Leontopoulou, SA1
Papadaki, EK1
Datseris, EI1
Anagnostopoulou, US1
Zerva, CJ1
Wysowski, DK1
Chang, JT1
Ringe, JD1
Dorst, A1
Faber, H1
Kipshoven, C1
Rovati, LC1
Setnikar, I1
Liang, JG1
Jiang, NY1
DU, JQ1
Lu, XP1
Liu, XG1
Chen, SX1
Wright, SA1
Millar, AM1
Coward, SM1
Finch, MB1
Honjo, S1
Yokote, K1
Takada, A1
Maezawa, Y1
Kobayashi, K1
Tokuyama, T1
Sonezaki, K1
Saito, Y1
Maini, CL2
Sciuto, R2
Romano, L1
Bergomi, S1
Carvalho, AP1
Bezerra, MM1
Girão, VC1
Cunha, FQ1
Rocha, FA1
van der Poel, HG1
Antonini, N1
Hoefnagel, CA1
Horenblas, S1
Valdes Olmos, RA1
Minutoli, F1
Herberg, A1
Spadaro, P1
Restifo Pecorella, G1
Baldari, S2
Aricò, D1
Altavilla, G1
Bingham, CO1
Buckland-Wright, JC1
Garnero, P1
Cohen, SB1
Dougados, M1
Adami, S2
Clauw, DJ1
Spector, TD1
Pelletier, JP1
Raynauld, JP1
Strand, V1
Simon, LS1
Meyer, JM1
Cline, GA1
Beary, JF1
Strigari, L1
D'Andrea, M1
Pasqualoni, R1
Benassi, M1
Felson, DT1
Kim, YJ1
Zonnenberg, BA1
Alexandre, CM1
Chapuy, MC1
Vignon, E1
Edouard, C1
Johnston, CC3
Meunier, PJ1
Licata, AA1
O'Hanlon, E1
Evans, RA1
MacDonald, D1
Merkow, RL1
Lane, JM1
Siris, ES3
Canfield, RE1
Jacobs, TP2
Baquiran, DC1
Rozing, PM1
Bohne, WH1
Insall, J1
Robinson, RG1
Preston, DF1
Schiefelbein, M1
Baxter, KG1
Wimalawansa, SJ1
Gunasekera, RD1
Recker, RR1
Palmedo, H3
Bender, H2
Schomburg, A1
Grünwald, F1
Schöneich, G1
Zamorra, P1
Reichmann, K1
Dierke-Dzierzon, C2
Mallmann, P1
Biersack, HJ3
Siris, E1
Weinstein, RS1
Altman, R1
Conte, JM1
Favus, M1
Lombardi, A1
Lyles, K1
McIlwain, H1
Murphy, WA1
Reda, C1
Rude, R1
Seton, M1
Tiegs, R1
Thompson, D1
Tucci, JR1
Yates, AJ1
Zimering, M1
Gloth, FM1
Schnur, W2
Paterson, AH1
Kanis, JA3
Powles, TJ1
McCloskey, E1
Hanson, J1
Ashley, S1
Body, JJ2
Coleman, RE1
Piccart, M1
McEwan, AJ1
Seleznev, AN1
Lipton, A1
Berenson, JR1
McCloskey, EV2
Hung, JC1
Appleton, RE1
Abernethy, L1
Hosking, DJ1
Eusebio, RA1
Chines, AA1
Holle, LH1
Humke, U1
Trampert, L1
Ziegler, M1
Kirsch, CM1
Oberhausen, E1
Maxon, HR3
Schroder, LE3
Washburn, LC1
Thomas, SR3
Samaratunga, RC2
Biniakiewicz, D1
Moulton, JS3
Cummings, D1
Ehrhardt, GJ1
Morris, V1
Miller, PD2
Brown, JP1
Hoseyni, MS1
Axelrod, DW1
Bekker, PJ1
Carl, UM1
Risse, J2
Krebs, D1
Róka, R1
Séra, T1
Pajor, L1
Thurzó, L1
Láng, J1
Csernay, L1
Pávics, L1
Israel, O1
Keidar, Z1
Rubinov, R1
Iosilevski, G1
Frenkel, A1
Kuten, A1
Betman, L1
Kolodny, GM1
Yarnitsky, D1
Front, D1
Küçük, NO1
Baltaci, S1
Ozalp, G1
Bedük, Y1
Canakci, N1
Soylu, A1
Franke, WG2
Koch, R1
Hliscs, R2
Bonabello, A1
Galmozzi, MR1
Bruzzese, T1
Zara, GP1
Okada, SF1
Dafermou, A1
Colamussi, P1
Giganti, M1
Cittanti, C1
Bestagno, M1
Piffanelli, A1
Kothari, K1
Samuel, G1
Unni, PR1
Chaudhari, PR1
Unnikrishnan, TP1
Pillai, MR1
Rockstroh, JK1
Bangard, M1
Schliefer, K1
Menzel, C1
Wang, J1
Zheng, X1
Wong, R1
Wiffen, PJ1
Ibbertson, HK1
Fraser, TR1
Scott, DJ1
Cullen, JC1
Henley, JW1
Stephens, ES1
Tait, B1
Wattie, DJ1
Rashid, M1
Khairi, A1
Johnston, C1
Khairi, MR2
Altman, RD2
DeRosa, GP1
Zimmermann, J1
Schenk, RK1
Rabens, SF1
Bethune, JE1
Hertzberg, VS2
Englaro, EE1
Samaratunga, R1
Scher, HI2
Deutsch, EA2
Deutsch, KF1
Libson, KF1
Williams, CC1
Laroche, M1
Arlet, P1
Mazières, B1
Arlet, J1
Melick, RA1
Ketring, AR1
Bird, HA1
Hill, J1
Sitton, NG1
Dixon, JS1
Wright, V1
Morales Piga, A1
García Vadillo, A1
Rodríguez García, A1
Elena Ibáñez, A1
Castro Beiras, JM1
Rodríguez Torrás, M1
Wellman, H1
Serafini, AN1
Sankey, RR1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026]Phase 370 participants (Anticipated)Interventional2020-03-02Recruiting
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention[NCT05204836]Phase 156 participants (Anticipated)Interventional2023-05-16Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

22 reviews available for etidronate and Pain

ArticleYear
Radionuclide therapy and integrated protocols for bone metastases.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2011, Volume: 55, Issue:4

    Topics: Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Etidronic Acid

2011
Stress fractures: diagnosis, treatment, and prevention.
    American family physician, 2011, Jan-01, Volume: 83, Issue:1

    Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Calcium, Diet

2011
Application of rhenium-188 HEDP in bone metastases therapy.
    Nuclear medicine review. Central & Eastern Europe, 2003, Volume: 6, Issue:1

    Topics: Bone Neoplasms; Etidronic Acid; Humans; Leukopenia; Organometallic Compounds; Pain; Palliative Care;

2003
186Re-HEDP for metastatic bone pain in breast cancer patients.
    European journal of nuclear medicine and molecular imaging, 2004, Volume: 31 Suppl 1

    Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Hum

2004
Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases.
    Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl

    Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Organophosphorus Compounds; Pain;

2003
The futility of current approaches to chondroprotection.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:5

    Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Cartilage, Articular; Chondrocytes; Doxycyc

2007
Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases.
    Anti-cancer agents in medicinal chemistry, 2007, Volume: 7, Issue:4

    Topics: Bone Neoplasms; Clinical Trials as Topic; Etidronic Acid; Humans; Medical Oncology; Models, Chemical

2007
Strontium 89 therapy for the palliation of pain due to osseous metastases.
    JAMA, 1995, Aug-02, Volume: 274, Issue:5

    Topics: Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Drugs, Investigational; Etidronic Acid; Fem

1995
Clinical review 41: Current therapy for osteoporosis.
    The Journal of clinical endocrinology and metabolism, 1993, Volume: 76, Issue:1

    Topics: Calcitonin; Calcium, Dietary; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Fluori

1993
Use of bisphosphonates in cancer patients.
    Cancer treatment reviews, 1996, Volume: 22, Issue:4

    Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid

1996
Unsealed source therapy of painful bone metastases: an update.
    Seminars in nuclear medicine, 1997, Volume: 27, Issue:2

    Topics: Bone Neoplasms; Clinical Trials as Topic; Etidronic Acid; Female; Humans; Male; Organometallic Compo

1997
Bisphosphonates and breast carcinoma.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic

1997
Bisphosphonates in multiple myeloma.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye

1997
Bisphosphonates in prostate carcinoma.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C

1997
Clodronate.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Etidronic Acid; Female; Hum

1997
The use of risedronate in Paget's disease.
    Bone, 1999, Volume: 24, Issue:5 Suppl

    Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Fibrous Dysplasia,

1999
Bisphosphonates in multiple myeloma.
    Cancer, 2000, Jun-15, Volume: 88, Issue:12 Suppl

    Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Pain; Pamid

2000
Bisphosphonates for the relief of pain secondary to bone metastases.
    The Cochrane database of systematic reviews, 2002, Issue:2

    Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Eti

2002
Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).
    Clinical orthopaedics and related research, 1977, Issue:127

    Topics: Alkaline Phosphatase; Bone and Bones; Calcitonin; Calcium; Deafness; Etidronic Acid; Fractures, Bone

1977
Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases.
    Seminars in nuclear medicine, 1992, Volume: 22, Issue:1

    Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Pain; Palliative Care

1992
Bone metastases and tumor-induced hypercalcemia.
    Current opinion in oncology, 1992, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho

1992
Treatment of Paget's disease of bone.
    The Medical journal of Australia, 1985, Oct-28, Volume: 143, Issue:9

    Topics: Analgesics; Antibody Formation; Calcitonin; Diphosphonates; Drug Resistance; Drug Therapy, Combinati

1985

Trials

25 trials available for etidronate and Pain

ArticleYear
Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
    Journal of nuclear medicine technology, 2013, Volume: 41, Issue:3

    Topics: Adult; Aged; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compo

2013
Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.
    Journal of bone and mineral metabolism, 2011, Volume: 29, Issue:5

    Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Female; Humans; Knee

2011
The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.
    Cancer biotherapy & radiopharmaceuticals, 2011, Volume: 26, Issue:2

    Topics: Blood Cell Count; Bone Neoplasms; Electrocardiography; Etidronic Acid; Female; Follow-Up Studies; Hu

2011
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:16

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Com

2012
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
    British journal of cancer, 2003, Aug-18, Volume: 89, Issue:4

    Topics: Aged; Aged, 80 and over; Blood Cell Count; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged

2003
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:1

    Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Etidronic Acid;

2005
Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2004, Volume: 48, Issue:3

    Topics: Bone Neoplasms; Carcinoma; Etidronic Acid; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organo

2004
Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study.
    Rheumatology international, 2005, Volume: 25, Issue:4

    Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Calcaneus; Calcium; Dietary Supplements;

2005
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Comb

2005
[186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2006, Volume: 50, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ma

2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro

2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro

2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro

2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro

2006
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
    Nuclear medicine communications, 2007, Volume: 28, Issue:8

    Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Et

2007
Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Calcified tissue international, 1993, Volume: 53, Issue:4

    Topics: Alkaline Phosphatase; Calcitonin; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Res

1993
[Pain therapy with rhenium-186 HEDP in multiple bone metastases].
    Nuklearmedizin. Nuclear medicine, 1996, Volume: 35, Issue:2

    Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Male; Neoplasm Met

1996
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
    The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids

1996
Bisphosphonates in multiple myeloma.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye

1997
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
    The American journal of medicine, 1999, Volume: 106, Issue:5

    Topics: Administration, Oral; Aged; Alkaline Phosphatase; Bone and Bones; Calcium Channel Blockers; Double-B

1999
[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Orvosi hetilap, 2000, May-07, Volume: 141, Issue:19

    Topics: Alkaline Phosphatase; Analgesics; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans;

2000
Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid

2000
[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
    Nuklearmedizin. Nuclear medicine, 2000, Volume: 39, Issue:6

    Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Leukocyte Count; Male; Middle Aged

2000
Analgesic effect of etidronate on degenerative joint disease.
    Journal of bone and mineral metabolism, 2001, Volume: 19, Issue:4

    Topics: Aged; Analgesics, Non-Narcotic; Back Pain; Bone Density; Dose-Response Relationship, Drug; Etidronic

2001
Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study.
    Radiology, 2001, Volume: 221, Issue:1

    Topics: Arthritis, Rheumatoid; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds;

2001
Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results.
    Annals of internal medicine, 1977, Volume: 87, Issue:6

    Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Matrix; Clinical Trials as Topic; Etidronic

1977
A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis.
    Clinical rheumatology, 1988, Volume: 7, Issue:1

    Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Bone and Bones; Clinical Trials as Topic; E

1988
Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).
    The New England journal of medicine, 1973, Dec-27, Volume: 289, Issue:26

    Topics: Administration, Oral; Aged; Alkaline Phosphatase; Bone and Bones; Clinical Trials as Topic; Dose-Res

1973

Other Studies

52 other studies available for etidronate and Pain

ArticleYear
In Vitro Evaluation of
    Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:5

    Topics: Bone Neoplasms; Cell Culture Techniques; Etidronic Acid; Female; Humans; Male; Organometallic Compou

2017
Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
    International journal of pharmaceutics, 2014, Apr-25, Volume: 465, Issue:1-2

    Topics: Animals; Bone Neoplasms; Etidronic Acid; Feasibility Studies; Humans; Male; Mice; Organometallic Com

2014
The Bisphosphonates Clodronate and Etidronate Exert Analgesic Effects by Acting on Glutamate- and/or ATP-Related Pain Transmission Pathways.
    Biological & pharmaceutical bulletin, 2016, Volume: 39, Issue:5

    Topics: Acetic Acid; Adenosine Triphosphate; Analgesics; Animals; Bone Density Conservation Agents; Capsaici

2016
A Freeze-Dried Kit for the Preparation of (188)Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation.
    Cancer biotherapy & radiopharmaceuticals, 2016, Volume: 31, Issue:4

    Topics: Bone Neoplasms; Etidronic Acid; Freeze Drying; Humans; Organometallic Compounds; Pain; Palliative Ca

2016
Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790.
    International journal of cancer, 2009, Sep-01, Volume: 125, Issue:5

    Topics: Acid Phosphatase; Animals; Behavior, Animal; Bone Density Conservation Agents; Bone Neoplasms; Bone

2009
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
    Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidro

2009
Heterotopic ossification in the residual lower limb in an adult nontraumatic amputee patient.
    American journal of physical medicine & rehabilitation, 2010, Volume: 89, Issue:3

    Topics: Adult; Alkaline Phosphatase; Amputation, Surgical; Bone Density Conservation Agents; Diabetic Foot;

2010
Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2011, Volume: 55, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Ka

2011
Potential genotoxic effect of 186Re-HEDP on human lymphocyte cells: in-vitro evaluation with micronucleus-FISH analysis.
    Nuclear medicine communications, 2012, Volume: 33, Issue:4

    Topics: Adult; Bone Neoplasms; Etidronic Acid; Female; Humans; In Situ Hybridization, Fluorescence; Lymphocy

2012
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study.
    Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:6

    Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Comorbidity;

2012
Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of anti-resorptive effects on bone.
    European journal of pharmacology, 2013, Jan-15, Volume: 699, Issue:1-3

    Topics: Acetic Acid; Analgesics; Animals; Capsaicin; Clodronic Acid; Corticosterone; Diphosphonates; Disease

2013
Radionuclide therapy of painful bone metastases--a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness.
    The American journal of hospice & palliative care, 2013, Volume: 30, Issue:8

    Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Pain; Palliative Care; Prostatic N

2013
Transient relief of metastatic cancer bone pain by oral administration of etidronate.
    Journal of bone and mineral metabolism, 2002, Volume: 20, Issue:4

    Topics: Administration, Oral; Aged; Alkaline Phosphatase; Analgesics, Non-Narcotic; Biomarkers; Bone and Bon

2002
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
    MMW Fortschritte der Medizin, 2002, Oct-31, Volume: 144, Issue:44

    Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents,

2002
Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
    Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:5

    Topics: Adult; Aged; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Follow-U

2003
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Calcified tissue international, 2004, Volume: 75, Issue:3

    Topics: Administration, Oral; Alkaline Phosphatase; Calcitriol; Clodronic Acid; Diphosphonates; Drug Toleran

2004
Alendronate and risedronate: reports of severe bone, joint, and muscle pain.
    Archives of internal medicine, 2005, Feb-14, Volume: 165, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bone and Bones; Child; Etidroni

2005
Chronic diffuse sclerosing osteomyelitis treated with risedronate.
    The Journal of rheumatology, 2005, Volume: 32, Issue:7

    Topics: Adult; Calcium Channel Blockers; Chronic Disease; Etidronic Acid; Female; Humans; Osteomyelitis; Pai

2005
Etidronate ameliorates painful soft-tissue calcification in Werner syndrome.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:11

    Topics: Adenosine Triphosphatases; Calcinosis; Connective Tissue; DNA Helicases; DNA Mutational Analysis; Et

2005
Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice.
    Clinical and experimental pharmacology & physiology, 2006, Volume: 33, Issue:7

    Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Diphosphonates;

2006
Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
    Urologia internationalis, 2006, Volume: 77, Issue:1

    Topics: Aged; Bone Neoplasms; Etidronic Acid; Hemoglobins; Humans; Male; Organometallic Compounds; Pain; Pre

2006
Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation.
    European journal of nuclear medicine and molecular imaging, 2007, Volume: 34, Issue:7

    Topics: Bone Neoplasms; Computer Simulation; Etidronic Acid; Humans; Models, Biological; Monte Carlo Method;

2007
Treatment of Paget's disease of bone with ethane-1, hydroxy-1,1 diphosphonate (EHDP) at a low dosage (5 mg/kg/day).
    Clinical orthopaedics and related research, 1983, Issue:174

    Topics: Adult; Aged; Alkaline Phosphatase; Blood Chemical Analysis; Cell Count; Drug Evaluation; Etidronic A

1983
Treatment of hyperparathyroidism with etidronate disodium.
    JAMA, 1983, Apr-15, Volume: 249, Issue:15

    Topics: Aged; Alkaline Phosphatase; Calcium; Etidronic Acid; Female; Humans; Hyperparathyroidism; Pain; Phos

1983
Diphosphonates and painful feet.
    Australian and New Zealand journal of medicine, 1983, Volume: 13, Issue:2

    Topics: Diphosphonates; Etidronic Acid; Female; Foot Diseases; Humans; Male; Middle Aged; Osteitis Deformans

1983
Current concepts of Paget's disease of bone.
    The Orthopedic clinics of North America, 1984, Volume: 15, Issue:4

    Topics: Arthritis; Calcitonin; Etidronic Acid; Fractures, Spontaneous; Humans; Joint Prosthesis; Osteitis De

1984
Long-term therapy of Paget's disease of bone with EHDP.
    Arthritis and rheumatism, 1980, Volume: 23, Issue:10

    Topics: Aged; Alkaline Phosphatase; Bone and Bones; Etidronic Acid; Female; Humans; Hydroxyproline; Long-Ter

1980
Bone scanning for the evaluation of knee prosthesis.
    Acta orthopaedica Scandinavica, 1982, Volume: 53, Issue:2

    Topics: Bone Cements; Etidronic Acid; Evaluation Studies as Topic; Humans; Knee Joint; Knee Prosthesis; Midd

1982
Extensive personal experience: Paget's disease of bone.
    The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:2

    Topics: Animals; Calcitonin; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pain; Pamidronate;

1995
Use of a bisphosphonate (etidronate) to improve metastatic bone pain in three hospice patients.
    The Clinical journal of pain, 1995, Volume: 11, Issue:4

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Female; Hospice Care; Humans; Male; Middle

1995
Etidronate and calcitonin for cancer bone pain.
    American family physician, 1996, Sep-15, Volume: 54, Issue:4

    Topics: Analgesics; Bone Neoplasms; Calcitonin; Drug Administration Schedule; Etidronic Acid; Humans; Pain

1996
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    The Canadian journal of oncology, 1995, Volume: 5 Suppl 1

    Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D

1995
[A pain syndrome of compression-reflex origin: the mechanisms of its development and the means for its therapeutic management].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997, Volume: 97, Issue:3

    Topics: Adult; Cervical Vertebrae; Chelating Agents; Combined Modality Therapy; Diphosphonates; Etidronic Ac

1997
Myositis ossificans complicating severe Guillain-Barré syndrome.
    Developmental medicine and child neurology, 1997, Volume: 39, Issue:11

    Topics: Adolescent; Cerebrospinal Fluid Proteins; Etidronic Acid; Humans; Immunoglobulins, Intravenous; Male

1997
Paget's disease of bone: reduction of disease activity with oral risedronate.
    Bone, 1998, Volume: 22, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Calcium; Calcium Channel Blocke

1998
[Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
    Der Urologe. Ausg. A, 1997, Volume: 36, Issue:6

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Male; Middle Aged;

1997
Rhenium-188(Sn)HEDP for treatment of osseous metastases.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1998, Volume: 39, Issue:4

    Topics: Aged; Animals; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds;

1998
Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases.
    Clinical nuclear medicine, 1999, Volume: 24, Issue:9

    Topics: Adult; Aged; Analgesics; Blood Cell Count; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female;

1999
Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
    Annals of nuclear medicine, 2000, Volume: 14, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lu

2000
Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
    Clinical nuclear medicine, 2000, Volume: 25, Issue:11

    Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Pain; Palliativ

2000
Analgesic effect of bisphosphonates in mice.
    Pain, 2001, Volume: 91, Issue:3

    Topics: Abdomen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates

2001
A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
    European journal of nuclear medicine, 2001, Volume: 28, Issue:7

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Humans; Injections, Intravenous; Male; Midd

2001
186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation.
    Nuclear medicine and biology, 2001, Volume: 28, Issue:6

    Topics: Analgesics; Animals; Bone Neoplasms; Etidronic Acid; Heterocyclic Compounds, 1-Ring; Injections, Int

2001
Rhenium-188 HEDP to treat painful bone metastases.
    Clinical nuclear medicine, 2001, Volume: 26, Issue:11

    Topics: Bone Neoplasms; Etidronic Acid; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Age

2001
Paget's disease of bone: assessment and management.
    Drugs, 1979, Volume: 18, Issue:1

    Topics: Aged; Alkaline Phosphatase; Analgesics; Calcitonin; Etidronic Acid; Humans; Hydroxyproline; Middle A

1979
Disodium etidronate therapy for dystrophic cutaneous calcification.
    Archives of dermatology, 1975, Volume: 111, Issue:3

    Topics: Abscess; Administration, Oral; Calcinosis; Elbow; Etidronic Acid; Female; Humans; Knee; Middle Aged;

1975
Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
    Radiology, 1990, Volume: 176, Issue:1

    Topics: Adenocarcinoma; Aged; Bone Neoplasms; Estrogens; Etidronic Acid; Humans; Male; Organometallic Compou

1990
[Efficacy of oral etidronic acid on pain and hypocalciuria in myeloma].
    Presse medicale (Paris, France : 1983), 1989, Sep-16, Volume: 18, Issue:28

    Topics: Administration, Oral; Aged; Calcium Metabolism Disorders; Etidronic Acid; Humans; Multiple Myeloma;

1989
Diagnosis and management of Paget's disease.
    Comprehensive therapy, 1986, Volume: 12, Issue:3

    Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Calcitonin; Etidronic Acid; Fractures, Bone; Humans; Mi

1986
Relief of metastatic bone pain with etidronate disodium.
    Ohio medicine : journal of the Ohio State Medical Association, 1987, Volume: 83, Issue:1

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Pain

1987
153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals.
    International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology, 1987, Volume: 14, Issue:3

    Topics: Animals; Bone Neoplasms; Dogs; Etidronic Acid; Humans; Kinetics; Organophosphorus Compounds; Pain; R

1987
[Usefulness of ethane-hydroxy-diphosphonate in the treatment of Paget's disease].
    Revista clinica espanola, 1985, Volume: 177, Issue:6

    Topics: Aged; Alkaline Phosphatase; Drug Evaluation; Etidronic Acid; Female; Humans; Hydroxyproline; Male; M

1985